Physician profile
David Allen Brown
NPI 1730269341
$7,103.94
in general payments reported to CMS, 2019-2025
11 companies · $2,134 in 2025
The $2,134 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $291 · 2021: $1,022 · 2022: $709 · 2023: $388 · 2024: $2,296 · 2025: $2,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,904 · Food and Beverage: $1,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,903.77 |
| Food and Beverage | $1,914.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,326.58 | 2019-2025 | Blueprint Patient Specific Instrumentation, Mako, Triathlon |
| Summit Surgical Corp. | $1,289.66 | 2024 | |
| Depuy Synthes Sales INC. | $1,226.27 | 2019-2025 | Na, Fibergraft Aeridyan Matrix, Tfn-Advance |
| Medical Device Business Services, INC. | $588.49 | 2021 | |
| Vericel Corporation | $222.88 | 2022 | |
| Merck Sharp & Dohme LLC | $172.98 | 2019-2023 | Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $122.03 | 2021 | |
| Nalu Medical, INC. | $68.48 | 2022-2024 | Nalu Neurostimulation System |
| Glaxosmithkline, LLC. | $47.01 | 2020 | |
| Alaska Medical Technologies, LLC | $39.56 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.